Effects of liraglutide versus lifestyle counselling on subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta-cell function after weight loss in metformin-treated obese patients with impaired glucose tolerance, impaired fasting glucose or newly diagnosed type 2 diabetes mellitus

Trial Profile

Effects of liraglutide versus lifestyle counselling on subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta-cell function after weight loss in metformin-treated obese patients with impaired glucose tolerance, impaired fasting glucose or newly diagnosed type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Glucose intolerance; Glucose metabolism disorders; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2017 Primary endpoint of change in VAT after achievement of theweight loss target has been met, according to results published in the Diabetes Care.
    • 14 Sep 2017 Results published in the Diabetes Care
    • 21 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top